Be up to date with the 2023 AMH Book or Online

This release includes 7 new monographs. Specific changes of interest include:

• the first SGLT2 inhibitor used for type 2 diabetes in children, dapagliflozin, is included for children >10 years
• treating severe allergic asthma with ‘mabs’ has expanded in the CDC with new monographs for benralizumab and mepolizumab, as well as expanding the dosing down to 6 years of age for dupilumab
• two new drugs, somatrogon and mecasermin, have been added to the Growth Hormone Program to treat growth failure or short stature
• a dose for adalimumab to treat paediatric ulcerative colitis
• two new monographs for dimethyl fumarate and teriflunomide to treat multiple sclerosis in children
• the approved paediatric uses for secukinumab have expanded to include juvenile idiopathic arthritis
• revised advice of the preferred NSAID of choice (naproxen) to treat the arthritic pain associated with acute rheumatic fever.

The AMH Aged Care Companion is our trusted, practical reference for health care professionals who work with older people.

The selected topics included in this companion reflect some of the most common illnesses and problems requiring drug treatment that confront the aged.

With every update, there are many changes to ensure the information remains current and relevant to the use of medicines in older people.

This release has new content and a number of changes. Updated topics that may be of interest include benign prostatic hyperplasia, constipation, dyspepsia, fall prevention, heart failure, hypertension, oedema, osteoarthritis, peripheral arterial disease, prostatitis, stroke prevention and urinary tract infection.

Many small but important changes are made in every update of the ACC; these are outlined in the Summary of key changes. You should make checking this summary one of the first things you do with every new release.